Follicular dendritic cells display microvesicle-associated LMP1 in reactive germinal centers of EBV+ classic Hodgkin lymphoma.
Classic Hodgkin lymphoma (cHL)
Epstein-Barr virus (EBV)
Exosomes and microvesicles
Follicular dendritic cells (FDCs)
Latent membrane protein-1 (LMP1)
Programmed death ligand 1 (PD-L1)
Journal
Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
received:
12
12
2018
accepted:
10
06
2019
revised:
06
06
2019
pubmed:
17
6
2019
medline:
28
7
2019
entrez:
17
6
2019
Statut:
ppublish
Résumé
Expression of the latent membrane protein-1 (LMP1) of Epstein-Barr virus (EBV) was investigated in 153 cases of EBV+ classic Hodgkin lymphoma (cHL); 120 cases were pediatric patients (< 14 years of age) from Iraq, and 33 cases were adult patients from Italy. We describe for the first time the presence of LMP1 protein in EBV-encoded RNA (EBER)-negative follicular dendritic cells (FDCs) of reactive germinal centers (GC) associated with EBV+ cHL. Presence of LMP1+ GCs was independent of geographic region and age of patients. Variable numbers of reactive GCs were present in 22.2% of cases (34 of 153), whereas LMP1 staining of FDCs was present in about a third of cases (10 of 34) with reactive GC. Most cases with LMP1+ GC were mixed-cellularity (MC) subtype, but some nodular sclerosis (NS) was also present. GC cells with LMP1+ FDCs were surrounded by numerous EBV-infected cells which were positive for EBER, LMP1, and CD30. Double immunolocalization analysis revealed that LMP1 was associated with CD63, an exosomal marker, and with CD21. The possibility is discussed that peri-follicular EBV-infected cells release LMP1 protein, perhaps through exosomes, and that the protein is then captured by FDCs and is presented to EBER-negative GC B cells.
Identifiants
pubmed: 31203443
doi: 10.1007/s00428-019-02605-w
pii: 10.1007/s00428-019-02605-w
pmc: PMC6647529
doi:
Substances chimiques
EBV-associated membrane antigen, Epstein-Barr virus
0
Viral Matrix Proteins
0
Types de publication
Journal Article
Langues
eng
Pagination
175-180Références
J Immunol. 2000 Jul 15;165(2):663-70
pubmed: 10878338
Immunity. 2000 Oct;13(4):497-506
pubmed: 11070168
Cancer. 2001 Sep 15;92(6):1621-31
pubmed: 11745241
EMBO J. 2003 Jun 16;22(12):3027-38
pubmed: 12805217
J Gen Virol. 2003 Jul;84(Pt 7):1871-9
pubmed: 12810882
Lancet. 1991 Feb 9;337(8737):320-2
pubmed: 1671232
Exp Cell Res. 2009 May 15;315(9):1584-92
pubmed: 18930046
Proc Natl Acad Sci U S A. 2010 Nov 23;107(47):20370-5
pubmed: 21059916
EMBO J. 2011 Jun 1;30(11):2115-29
pubmed: 21527913
Pediatr Blood Cancer. 2013 Dec;60(12):2068-72
pubmed: 24000236
Trends Immunol. 2014 Mar;35(3):105-13
pubmed: 24315719
J Gen Virol. 1987 Jun;68 ( Pt 6):1575-86
pubmed: 2438376
J Pathol. 2015 Jan;235(2):312-22
pubmed: 25294567
Hum Pathol. 2015 May;46(5):716-24
pubmed: 25704629
J Virol. 2017 Feb 14;91(5):
pubmed: 27974566
Cancer Res. 2017 Jul 1;77(13):3685-3699
pubmed: 28536276
Blood. 2017 Nov 30;130(22):2420-2430
pubmed: 28893733
Blood. 2018 Jul 5;132(1):17-22
pubmed: 29716887
Pediatr Blood Cancer. 2018 Dec;65(12):e27399
pubmed: 30207048